Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Feb 20, 2020 11:22pm
69 Views
Post# 30716026

RE:RE:RE:RE:RE:Genfit -unusual news

RE:RE:RE:RE:RE:Genfit -unusual newsIt's funny, I don't know if you were trying to be sarcastic and point out that the over analysis is futile. At the end of the day it doesn't matter if the goalposts are a mile wide or just feet apart, if TH doesn't know where they are then the team is just running around the field wasting time and energy. For us as spectators, who wants to buy tickets to watch a nonsense game. The big news will be when everyone, player and spectators, know where the goals are. That's when the game gets exciting.
palinc2000 wrote:

So it could be a net positive or a net negative for TH
It seems that the goal posts are either  being moved or are wider apart

 

SPCEO1 wrote: I would hope we would know all the key parts of this prior to May and it sounds like we will.

 

 

qwerty22 wrote:

It sounds to me like exactly what you are saying and I can't see how it isn't relevant to the whole industry. Who knows maybe Theratech are treading water as well waiting for this announcement. It's not like they'd tell us if they where. Definitely a topic to raise while schmoozing with insiders at an annual meeting, maybe (hint)

 

SPCEO1 wrote: That is a head scratcher. Could the FDA be about to issue new guidance of some sort on NASH and told Genfit there was no point in issuing their results prior to that? If you hear anything about this, i would be interested in hearing it too. It may have an impact on TH. I suspect not but would like to what might be going on witht he FDA.
 

 


 

 






Bullboard Posts